Patricia Coelho de Soarez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1620717/publications.pdf

Version: 2024-02-01

81 papers 936 citations

471509 17 h-index 25 g-index

90 all docs 90 docs citations

90 times ranked 1368 citing authors

#	Article	IF	Citations
1	Multicriteria decision analysis in health care decision in oncology: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 365-380.	1.4	3
2	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. PLoS ONE, 2022, 17, e0268584.	2.5	5
3	Critérios de decisão para a alocação de recursos: uma análise de relatórios da CONITEC na área de oncologia. Ciencia E Saude Coletiva, 2022, 27, 2563-2572.	0.5	O
4	Decision criteria for resource allocation: an analysis of CONITEC oncology reports. Ciencia E Saude Coletiva, 2022, 27, 2563-2572.	0.5	1
5	Hospital-based health technology assessment in Brazil: current experiences and challenges. International Journal of Technology Assessment in Health Care, 2021, 37, .	0.5	2
6	Effects of 3D image-guided brachytherapy compared to 2D conventional brachytherapy on clinical outcomes in patients with cervical cancer: A systematic review and meta-analyses. Brachytherapy, 2021, 20, 710-737.	0.5	14
7	Factors Associated with the Costs of Palliative Care: A Retrospective Cost Analysis at a University Cancer Hospital in Brazil. Journal of Palliative Medicine, 2021, 24, 1481-1488.	1.1	3
8	A Mobile Health Intervention for Patients With Depressive Symptoms: Protocol for an Economic Evaluation Alongside Two Randomized Trials in Brazil and Peru. JMIR Research Protocols, 2021, 10, e26164.	1.0	0
9	Health Technology Assessment: informed by science or in the service of politics?. Revista De Saude Publica, 2021, 55, 64.	1.7	1
10	Avaliação de Tecnologias em Saúde: informada pela ciência ou a serviço da polÃŧica?. Revista De Saude Publica, 2021, 55, 64.	1.7	1
11	Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil. Vaccine, 2020, 38, 46-53.	3.8	3
12	Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. Cancers, 2020, 12, 1929.	3.7	49
13	Health technology assessment of biosimilars worldwide: a scoping review. Health Research Policy and Systems, 2020, 18, 95.	2.8	10
14	Cross-cultural adaptation of the NoMAD questionnaire to Brazilian Portuguese. Revista Da Associação Médica Brasileira, 2020, 66, 1383-1390.	0.7	7
15	Participação social na gestão de tecnologias em saúde em âmbito federal no Brasil. Revista De Saude Publica, 2020, 54, 136.	1.7	1
16	Economic evaluation of adolescents and adults' pertussis vaccination: A systematic review of current strategies. Human Vaccines and Immunotherapeutics, 2019, 15, 14-27.	3.3	19
17	Doenças raras, drogas órfãs e as polÃticas para avaliação e incorporação de tecnologias nos sistemas de saúde. Sociologias, 2019, 21, 332-364.	0.3	7
18	Systematic review of health economic evaluation studies of dengue vaccines. Vaccine, 2019, 37, 2298-2310.	3.8	12

#	Article	IF	Citations
19	Palliative cancer care: costs in a Brazilian quaternary hospital. BMJ Supportive and Palliative Care, 2019, , bmjspcare-2019-001809.	1.6	5
20	Intercambialidade e substituição de biossimilares: seria a avaliação de tecnologias em saúde (ATS) um instrumento para tomada de decisão?. Cadernos De Saude Publica, 2019, 35, e00087219.	1.0	5
21	Integrated care pathway for rectal cancer treatment: cross-sectional post-implementation study using a logic model framework. Sao Paulo Medical Journal, 2019, 137, 438-445.	0.9	O
22	Early Palliative Care and Its Impact on End-of-Life Care for Cancer Patients in Brazil. Journal of Palliative Medicine, 2018, 21, 659-664.	1.1	18
23	Challenges of interpreting epidemiologic surveillance pertussis data with changing diagnostic and immunization practices: the case of the state of São Paulo, Brazil. BMC Infectious Diseases, 2018, 18, 126.	2.9	16
24	Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60†years of age or older. Vaccine, 2018, 36, 2510-2522.	3.8	10
25	Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation. Revista De Saude Publica, 2018, 52, 94.	1.7	9
26	Modalidades de gestão de serviços no Sistema Único de Saúde: revisão narrativa da produção cientÃfica da Saúde Coletiva no Brasil (2005-2016). Cadernos De Saude Publica, 2018, 34, e00114217.	1.0	9
27	Systematic Review of Health Economic Evaluation Studies Developed in Brazil from 1980 to 2013. Frontiers in Public Health, 2018, 6, 52.	2.7	16
28	Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations. Health Research Policy and Systems, 2018, 16, 40.	2.8	24
29	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. International Journal of Cardiology, 2018, 273, 63-68.	1.7	5
30	Health Economic Evaluations of Cancer in Brazil: A Systematic Review. Frontiers in Public Health, 2018, 6, 205.	2.7	6
31	Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening. Clinics, 2018, 73, e385.	1.5	7
32	A systematic review of health economic evaluations of vaccines in Brazil. Human Vaccines and Immunotherapeutics, 2017, 13, 1454-1465.	3.3	7
33	Vaccines are different: A systematic review of budget impact analyses of vaccines. Vaccine, 2017, 35, 2781-2793.	3.8	8
34	COST-EFFECTIVENESS ANALYSIS AND QUALITY OF LIFE OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTING: MASS III TRIAL 5-YEAR FOLLOW-UP. Journal of the American College of Cardiology, 2017, 69, 100.	2.8	0
35	Integrated care pathway for rectal cancer treatment. International Journal of Evidence-Based Healthcare, 2017, 15, 53-62.	0.5	3
36	Many Miles to Go: A Systematic Review of the State of Cost-Utility Analyses in Brazil. Applied Health Economics and Health Policy, 2017, 15, 163-172.	2.1	3

#	Article	IF	CITATIONS
37	Retrospective Analysis of the Use of Incremental Cost-Effectiveness Ratio (Icer) in Technology Incorporation in the Brazilian Public Health System (Sus), 2012-2016, Perspectives and Challenges for the Brazilian Context. Value in Health, 2017, 20, A908.	0.3	O
38	Systematic Review Of Economic Evaluation Studies For Dengue Vaccine: How Valid Are The Results?. Value in Health, 2017, 20, A932.	0.3	1
39	Limiares de custo-efetividade e o Sistema Único de Saúde. Cadernos De Saude Publica, 2017, 33, e00040717.	1.0	30
40	Systematic Review of Health Economic Evaluations of Diagnostic Tests in Brazil: How accurate are the results?. Clinics, 2017, 72, 499-509.	1.5	2
41	Health technology assessment (HTA) organizations: dimensions of the institutional and political framework. Cadernos De Saude Publica, 2016, 32, e00022315.	1.0	19
42	Cross-cultural adaptation of the CDC Worksite Health ScoreCard questionnaire into Portuguese. Revista Da Associação Médica Brasileira, 2016, 62, 236-242.	0.7	7
43	Evaluation of an Integrated Care Pathway for Rectal Cancer Treatment Implementation Using a Logic Model. Value in Health, 2016, 19, A22.	0.3	0
44	Comparative Effectiveness Research in Developing Countries: Example of Brazil., 2016, , 149-159.		0
45	Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil. Vaccine, 2016, 34, 1531-1539.	3.8	22
46	Economic evaluations in gastroenterology in Brazil: A systematic review. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 162.	1.1	1
47	Analysis of the Reports of the National Committee for Technology Incorporation (Conitec) in the Brazilian Public Health System (Sus), 2012-2015. Value in Health, 2015, 18, A522-A523.	0.3	0
48	Comparação De Tratamentos Para Câncer De Cabeça E Pescoço Ajustado Por Escore De Propensão: Radioterapia Versus Cirurgia+Radioterapia. Value in Health, 2015, 18, A816.	0.3	0
49	Healthcare resource utilization and costs of outpatient follow-up after liver transplantation in a university hospital in São Paulo, Brazil: cost description study. Sao Paulo Medical Journal, 2015, 133, 171-178.	0.9	4
50	Methods and challenges for the health impact assessment of vaccination programs in Latin America. Revista De Saude Publica, 2015, 49, .	1.7	5
51	Quality of life evaluation of frail elderly in Campinas, São Paulo. Revista Da Associação Médica Brasileira, 2015, 61, 423-430.	0.7	13
52	Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics, 2015, 70, 289-295.	1.5	16
53	Use of Incremental Cost-Effectiveness Ratio (Icer) in Recommending Technologies Incorporation in the Brazilian Public Health System (Sus), 2012-2015. Value in Health, 2015, 18, A523.	0.3	3
54	Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil. Vaccine, 2015, 33, A135-A142.	3.8	18

#	Article	IF	CITATIONS
55	Polio inactivated vaccine costs into routine childhood immunization in Brazil. Revista De Saude Publica, 2015, 49, 8.	1.7	7
56	Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil. PLoS ONE, 2015, 10, e0130217.	2.5	18
57	Comparative Effectiveness Research in Developing Countries: Example of Brazil., 2015, , 1-11.		0
58	Modelling the Force of Infection for Hepatitis A in an Urban Population-Based Survey: A Comparison of Transmission Patterns in Brazilian Macro-Regions. PLoS ONE, 2014, 9, e94622.	2.5	30
59	Economic Evaluation Studies In Gastroenterology In Brazil: A Systematic Review. Value in Health, 2014, 17, A368.	0.3	0
60	Systematic Review of Economic Evaluation of Health Technologies Developed In Brazil From 1980-2013. Value in Health, 2014, 17, A438.	0.3	4
61	Systematic Review of Economic Evaluations in Cancerology In Brazil Between 1980 And 2013. Value in Health, 2014, 17, A661.	0.3	0
62	Introduction of universal human papillomavirus vaccination of girls aged 11 years to the National Immunization Program in Brazil: a cost-effectiveness analysis. Lancet, The, 2014, 384, S19.	13.7	0
63	Estimating health service utilization for treatment of pneumococcal disease: The case of Brazil. Vaccine, 2013, 31, C63-C71.	3.8	5
64	Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. Journal of Epidemiology and Community Health, 2012, 66, 210-217.	3.7	35
65	Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: Regional analyses according to the endemic context. Vaccine, 2012, 30, 7489-7497.	3.8	32
66	Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil. Cadernos De Saude Publica, 2012, 28, 211-228.	1.0	8
67	A importância dos métodos de custeio e valoração nas avaliações econômicas em saúde: repercussõe sobre os resultados de avaliação da vacina antimeningocócica C. Physis, 2012, 22, 641-658.	²⁸ 0.3	0
68	Cost-Effectiveness Analysis of a Universal Infant Immunization Program with Meningococcal C Conjugate Vaccine in Brazil. Value in Health, 2011, 14, 1019-1027.	0.3	18
69	Health technology assessment in Brazil: what do healthcare system players think about it?. Sao Paulo Medical Journal, 2011, 129, 198-205.	0.9	15
70	Hospitalization rates for pneumococcal disease in Brazil, 2004 - 2006. Revista De Saude Publica, 2011, 45, 539-547.	1.7	19
71	Cost-effectiveness analysis on spinal anesthesia versus local anesthesia plus sedation for loop colostomy closure. Arquivos De Gastroenterologia, 2010, 47, 159-164.	0.8	5
72	Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. Sao Paulo Medical Journal, 2009, 127, 295-301.	0.9	5

#	Article	IF	CITATIONS
73	A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment. Arquivos De Gastroenterologia, 2009, 46, 241-247.	0.8	16
74	The Effect of Identifying Macroprolactinemia on Health-Care Utilization and Costs in Patients with Elevated Serum Prolactin Levels. Value in Health, 2009, 12, 930-934.	0.3	12
75	PIN52 COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL. Value in Health, 2009, 12, A427.	0.3	2
76	Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?. Cadernos De Saude Publica, 2009, 25, S401-S414.	1.0	15
77	Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine, 2008, 26, 6281-6291.	3.8	41
78	Rotavirus morbidity and mortality in children in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 92-100.	1.1	37
79	Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 221-230.	1.1	36
80	Health care costs in the last four years of life for private health plan beneficiaries in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 24, 120-6.	1.1	3
81	The Brazilian Portuguese version of the Work Productivity and Activity Impairment: General Health (WPAI-GH) Questionnaire. Sao Paulo Medical Journal, 2006, 124, 325-332.	0.9	37